ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
72 announcements with these filters
Zydus delivered robust FY27 Q1 results driven by strong India-branded formulations and U.S. generic resilience.
Zydus Lifesciences reported a contra trade violation by a designated person under SEBI PIT Regulations. The profit of Rs. 18,797 was transferred to the IEPF.
Zydus Lifesciences' subsidiary, Sentynl Therapeutics, signed an option and license agreement with Mereo BioPharma for alvelestat. The deal includes upfront and R&D payments totaling 380 Crore.
Zydus Lifesciences reported strong Q1 FY27 revenue growth of 22% YoY, driven by robust performance in India and International formulations, despite a decline in PAT and EBITDA margins.
Zydus Lifesciences Ltd reported revenue from operations of ₹8,017 Cr (+22.0% YoY) and net profit of ₹939.8 Cr (-35.9% YoY) for Q1 FY27.
Zydus Lifesciences launched REVAHALE, India's first once-daily nebulised LAMA for COPD treatment. This therapy offers 24-hour bronchodilation for patients unable to use standard handheld inhalers.
Zydus Lifesciences received final USFDA approval for Indocyanine Green for Injection with 180-day exclusivity. The reference brand had annual U.S. sales of approximately USD 125.8 million.
Zydus Lifesciences received an Establishment Inspection Report (EIR) from the USFDA for its Ahmedabad injectable facility, with a 'Voluntary Action Indicated' (VAI) classification.
Zydus Lifesciences received a demand for ₹108.54 Crore in deficient stamp duty and penalties. The company is evaluating legal remedies regarding the order.
Zydus Lifesciences received approval for a Phase III clinical trial of Desidustat for Sickle Cell Disease. The trial is conducted in collaboration with ICMR.
Zydus Lifesciences scheduled a board meeting for August 11, 2026. The board will consider and approve unaudited financial results for the quarter ended June 30, 2026.
Zydus Lifesciences clarified that a Delhi High Court order restricting supply of its cancer drug Ikra is not material. The company reports no material business impact.
Zydus Lifesciences submitted its Business Responsibility and Sustainability Report for FY 2025-26. The report details ESG metrics, workforce statistics, and CSR compliance for the period.
Zydus Lifesciences filed its Integrated Annual Report for FY 2025-26 and announced the AGM scheduled for August 11, 2026. The filing includes the AGM notice and report link.
Zydus Lifesciences Ltd will hold its AGM on 11 August 2026. The notice includes voting deadlines and dividend payment details.
Zydus Lifesciences announced an MoU with Apollo Hospitals to bring the Shield™ Multi‑Cancer Detection test to India. The partnership aims to expand cancer screening across the country.
Zydus Lifesciences is acquiring the API business of Sterling Biotech for Rs.84 Crore. The deal, delayed to Sep‑30‑2026, adds fermentation‑based products to its portfolio.
Zydus Lifesciences extended the closing date for its acquisition of Sterling Biotech’s API business to September 30, 2026. The deal remains pending completion.
Zydus Lifesciences formed a 50:50 joint venture in Sri Lanka. The investment is valued at up to ₹47 Crore.
Zydus Lifesciences completed the acquisition of Assertio Holdings Inc. for ₹156.35 Crore. Assertio becomes a wholly owned subsidiary, expanding Zydus' oncology portfolio.
Zydus Lifesciences completed the acquisition of Assertio Holdings via a cash tender offer. Assertio will become a wholly owned subsidiary, expanding Zydus' global portfolio.
Zydus Lifesciences' subsidiary ZHL secured favorable appellate orders dropping GST demands totaling ₹0.42 Crore. This significantly reduces the company's potential tax liability and penalty exposure.
Zydus Lifesciences received a USFDA Warning Letter regarding its Baddi facility's purified talc technical observations. The company expects no impact on current operations or supplies.
Zydus Lifesciences received US FDA Priority Review for its Saroglitazar NDA. This regulatory milestone accelerates the potential US launch for Primary Biliary Cholangitis treatment.
Zydus Lifesciences increased its share buyback price to ₹1,260 per share for a ₹1,100 Crore total offer. Maximum shares reduced to 87,30,158.
Zydus Lifesciences received US FDA Priority Review for its saroglitazar NDA. The PDUFA target action date is set for November 27, 2026, boosting product pipeline visibility.
Zydus Lifesciences reported the transmission of 10,000 shares within its promoter group. The transaction reflects internal succession planning and does not change aggregate promoter control.
Zydus delivered strong Q4 FY26 results with 16% YoY revenue growth and record 33.7% EBITDA margins, driven by US specialty and India branded formulations.
Zydus Lifesciences submitted its Annual Secretarial Compliance Report for FY2026. The report noted a minor technical delay in board meeting intimation resulting in total fines of ₹23,600.
Zydus Lifesciences invested ₹9.02 Crore to complete its subscription in Torrent Urja 25. The company now holds a 22.06% stake in the entity.